Introduction
Substantial evidence suggests that mammalian fluids and tissues contain endogenous factors with digitalislike activity (EDLF: endogenous digitalislike factor) that may be involved in hydro-saline homeostasis and in some forms of hypertension (1, 2). The first EDLF to be characterized from human plasma was ouabain (3), but other EDLFs, including digoxinlike factors (4) and bufodienolide derivatives (5, 6) have also been identified.
The existence of a family of EDLFs might be related to the presence of different isoforms of the Na+,K+-ATPase in mammalian tissues (7) with potentially different responsiveness to various EDLFs (8, 9) .
Recent papers (5, 10) suggest that EDLFs may also be involved in compensatory responses to hypoxia. Bagrov et al. (5) have reported that hypoventilation in humans produces a marked increase in the plasma levels of marinobufagenin-like immunoreactivity and inhibition of the Na+,K+-ATPase in intact erythrocytes. Hypoxia has also been found to stimulate the release of a Na+,K+-ATPase inhibitor (10) both from the rat midbrain and adrenal tissue that co-chromathographs with a hypothalamic EDLF identified in the bovine (11). Higher plasma and urine digoxinlike immunoreactivity has been reported in normal subjects during prolonged hypoxic breathing at high altitudes (12) and in patients with chronic obstructive pulmonary disease (13). Finally, the finding of high EDLF levels in the newborn (14-16) may also be related to the well-known hypoxic condition at birth. Obstructive sleep apnea (OSA) represents another condition in which the effects of hypoxia on EDLFs can be studied. OSA is a relatively common condition that occurs when attempts to breathe are blocked by an occluded upper airway and is characterized by snoring, frequent arousals during sleep, and daytime somnolence (17) . The frequency of apneic episodes is often more than 20 per hour of sleep. Apneic episodes are associated with nighttime sympathetic activation (18). Patients with OSA are believed to be at high risk of developing hypertension (19), cardiac arrhythmias, and ischemic heart disease (20). Most patients with OSA are moderately to severely obese.
Based on the belief that the human EDLFs can be detected more appropriately with human rather than animal Na+,K+-ATPase, we have developed a radioreceptor assay (RRA) using membranes from human placentas as receptors (15) .
The intent of this study was to measure EDLFs of different hydrophobicities in the plasma of patients with obstructive sleep apnea and to relate these findings to a few indices related to this disease.
Subjects and Methods
We studied 10 male patients with OSA (8 normotensives and 2 hypertensives) and 11 age-matched healthy male controls belonging to our laboratory staff. All subjects gave informed consent, and the study was approved by the local Committee. Patients were diagnosed by polysomnography and classified on the basis of the apneahypopnea index (AHI). All patients were severely ill, since they had more than 30 episodes of apnea and hypopnea per hour. None had clinical or biochemical evidence of renal, cardiac, or endocrinological diseases, had ever taken digitalis drugs, or was taking any medication. Clinical characteristics of the subjects are reported in Table 1 . Peripheral blood samples were drawn in the morning into Vacutainer tubes containing sodium heparin for EDLF detection and EGTA/glutathione for catecholamine analysis.
For the measurement of EDLFs, plasma (2 ml) was extracted through C18 SepPak cartridges (Waters Inc., Cambridge, USA) activated with 5 ml of acetonitrile (ACN) and equilibrated with 20 ml of 0.1% trifluoroacetic acid (TFA). After washing with 10 ml of 0.1% TFA, EDLFs of different hydrophobicity were eluted with 3 ml of 25% ACN in 0.1% TFA (fraction 1) followed by 3 ml of 40% ACN in 0.1% TFA (fraction 2). Both eluates were vacuum-dried and kept at -20°C until assayed. Extracts were reconstituted in 0.25 ml of buffer (15) and analyzed by the human placenta radioreceptor assay (RRA) using ouabain calibrators, as previously described (15) . EDLF values were expressed in ouabain-equivalents (o . e .) . The assay sensitivity was 0.32±0.02 nM (0.16 pmol/tube).
In preliminary experiments we found that, by this extraction procedure, ouabain was completely recovered (98% of the added compound) in the first fraction, and the more hydrophobic digitalis compounds such as digoxin (98% of the added compound), digitoxigenin (64%), and digitoxin (45%) in the second fraction. In the second fraction were also eluted some common adrenocortical steroids (cortisol, cortisone, corticosterone, estradiol, aldosterone and, in lesser amounts, dehydroepiandrosterone sulfate, and progesterone), but the high specificity of the human placenta digitalis receptor (15) and the lack of binding inhibition by C18 extracts of steroids-free plasma spiked with concentrations of steroids much higher than those remaining after plasma extraction makes it very unlikely that the EDLFs measured in this fraction represent an interference due to these steroids.
Plasma catecholamines were analyzed by the automated HPLC analyzer HLC 725 (Tosoh Co., Tokyo, Japan) after the precipitation of proteins with perchloric acid (21).
In an initial attempt to characterize digitalislike activity eluted through C18 cartridges, the two eluates from a cartridge were fractionated by reverse-phase HPLC on a C18 u-Bondapak column (3.9X300 mm) with a linear gradient of acetonitrile/TFA 0.1% (10% to 100%) over 40 min at 1 ml/min. One-minute fractions were collected, vacuumdried, and assessed by RRA (15) .
The data are expressed as mean±SEM. Data were compared using ANOVA and regression analysis.
Results
The levels of circulating factors interacting with the human placenta digitalis receptor are reported in Fig. 1 . EDLFs in fraction 1 were similar for normotensive OSA patients (231 ± 55 pM o. e.) and controls (258 ± 58 pM o.e.), whereas significantly higher EDLF values were found in fraction 2 for normotensive OSA patients as compared to controls (244±51 pM o. e. vs. 110±25 pM o.e., p=0.02). EDLF levels in fraction 2 from the two hypertensive OSA patients (200 pM o.e. and 395 pM o.e.) were in the same range as in those without hypertension.
Circulating levels of norepinephrine in OSA patients (774±111 pg/ml) were higher than reference values (179-677 pg/ml). Plasma epinephrine (E) and dopamine (D) levels were in the normal range. No significant correlation was found in the OSA patients between the EDLF values in fractions 1 and 2 and plasma norepinephrine, AHI or lowest oxygen hemoglobin saturation. HPLC fractionation of fraction 1 resulted in a single active fraction with a retention time identical to that of authentic ouabain (10.13 min) (Fig. 2) . A more complex profile with a broad peak spanning from that of ouabain to that of digoxin (14.17 min) was found with fraction 2 (Fig. 2) . 
Discussion
Recent studies in rats (10) and humans (5, 12, 13) suggest that hypoxia may be a stimulus for the release of digitalislike factors.
In this preliminary study, we used first a solid-state extraction in two steps to sepatate EDLFs of different hydrophobicities from the same plasma sample, and then human placenta RRA was used for detection (15) . By this method, we observed an increase in the more hydrophobic circulating EDLFs in obstructive sleep apnea, both in the normotensive and hypertensive state.
These data appear to be in accordance with those obtained by Bagrov (5), who has reported increased levels of marinobufagenin in voluntary hypoventilation. However, a direct comparison cannot be made since we have not determined in which C18-fraction marinobufagenin (which is more hydrophobic than ouabain and less than digoxin) is eluted. Moreover, our patients were studied in the morning, when normoxic conditions were restored. After the cessation of hypoventilatory breathing, the increased levels of marinobufagenin-like immunoreactivity have been reported on average to decline and the activity of Na+,K+-ATPase to be restored (5).
In this study we found no significant difference between OSA patients and controls for the ouabainlike, less-hydrophobic EDLF collected with 25% ACN. Whether this result is due to the small number of subjects studied or confirms the results of Bagrov et al. (5), who did not find an increase in the plasma levels of ouabainlike immunoreactivity in response to voluntary hypoventilation in humans, remains to be established. On the other hand, hypoxia has been reported to stimulate the release of an ouabainlike Na+,K+-ATPase inhibitor from rat tissues both in vivo and in vitro (10), and De Angelis et al. (12, 13) have reported high levels of digoxinlike immunoreactivity in normal subjects during prolonged hypoxic breathing at high altitudes, although they did not analyze ouabainlike activity.
Like others, we found that plasma norepinephrine levels are increased in apneics, but we were not able to demonstrate a relation between EDLF levels and humoral and clinical indices of the severity of the disease. However, we cannot exclude such a relation because of the still limited number of subjects studied, and because of the EDLF levels being measured under normoxemic conditions and control subjects not being included in the correlations.
In conclusion, these preliminary results suggest that obstructive sleep apnea is associated with an increase in the level of more hydrophobic EDLFs. No significant increase was found in the present study for the less-hydrophobic ouabainlike EDLF. The functional significance of increased EDLF levels in hypoxia remains to be established. As proposed by others (12), since a large fraction of oxygen and energy is utilized by the body for active sodium and potassium transport mediated by the sodium pump, a mechanism that slows the activity of the sodium pump, such as, perhaps, one associated with EDLFs, might represent a useful compensatory system in conditions of insufficient oxygen availability.
